Xabier Pérez de Mendiola1,2, Diego Hidalgo-Mazzei3, Eduard Vieta3, Ana González-Pinto4,3. 1. Bioaraba, Research Group on Severe Mental Illness; Osakidetza, Araba University Hospital, Psychiatry Service; Faculty of Medicine, Department of Neurosciences, University of the Basque Country UPV / EHU, Vitoria-Gasteiz, Spain. xabier.perezdemendiolaetxezarraga@osakidetza.eus. 2. Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, Centre for Biomedical Research Network on Mental Health (CIBERSAM), Barcelona, Spain. xabier.perezdemendiolaetxezarraga@osakidetza.eus. 3. Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, Centre for Biomedical Research Network on Mental Health (CIBERSAM), Barcelona, Spain. 4. Bioaraba, Research Group on Severe Mental Illness; Osakidetza, Araba University Hospital, Psychiatry Service; Faculty of Medicine, Department of Neurosciences, University of the Basque Country UPV / EHU, Vitoria-Gasteiz, Spain.
Abstract
BACKGROUND: Lithium is considered the gold standard treatment for bipolar disorder (BD). Current clinical guidelines and scientific evidence support its use as a first-line treatment in BD. However, over the last two decades, there has been a downward tendency in lithium's use in several developed countries. Based on a nationwide survey, this study's objective is to analyze in a large sample of psychiatrists relevant issues of the use of lithium salts in BD. METHODS: Data were collected through an anonymous survey sent by email among 500 psychiatrists who belong to a National Society of Psychiatry (Spanish Society of Biological Psychiatry). The survey is a self-administered questionnaire consisting of 21 items on the most key aspects of lithium's use (indication, dosage, monitoring, and information for patients). RESULTS: 212 psychiatrists completed the survey. 70% of psychiatrists prescribe lithium to more than 50% of patients diagnosed with BD. Adverse effects are the main reason not to use lithium salts. Over 75% of the participants consider lithium salts the treatment of choice for the maintenance phase of BD, both in women and men. Most of the participants (> 50%) start lithium after the first affective episode, use conservative plasma concentrations (0.6-0.8 mmol/L), and generally prescribe it twice a day. 57% of psychiatrists who treat patients under 18 do not use lithium in this population. About 70% of the survey respondents use official protocols to inform and monitor patients on lithium treatment. CONCLUSIONS: From the results of the present study, it can be concluded that the use of lithium in Spain is in line with the recommendations of the main international clinical guidelines and current scientific literature. The first reason not to prescribe lithium in our country is the perception of its adverse effects and not the aspects related to its practical use or its effectiveness. Considering that BD is a chronic disease with a typical onset in adolescence, the low rate of prescription of lithium salts in patients under 18 must be thoroughly studied.
BACKGROUND:Lithium is considered the gold standard treatment for bipolar disorder (BD). Current clinical guidelines and scientific evidence support its use as a first-line treatment in BD. However, over the last two decades, there has been a downward tendency in lithium's use in several developed countries. Based on a nationwide survey, this study's objective is to analyze in a large sample of psychiatrists relevant issues of the use of lithium salts in BD. METHODS: Data were collected through an anonymous survey sent by email among 500 psychiatrists who belong to a National Society of Psychiatry (Spanish Society of Biological Psychiatry). The survey is a self-administered questionnaire consisting of 21 items on the most key aspects of lithium's use (indication, dosage, monitoring, and information for patients). RESULTS: 212 psychiatrists completed the survey. 70% of psychiatrists prescribe lithium to more than 50% of patients diagnosed with BD. Adverse effects are the main reason not to use lithium salts. Over 75% of the participants consider lithium salts the treatment of choice for the maintenance phase of BD, both in women and men. Most of the participants (> 50%) start lithium after the first affective episode, use conservative plasma concentrations (0.6-0.8 mmol/L), and generally prescribe it twice a day. 57% of psychiatrists who treat patients under 18 do not use lithium in this population. About 70% of the survey respondents use official protocols to inform and monitor patients on lithium treatment. CONCLUSIONS: From the results of the present study, it can be concluded that the use of lithium in Spain is in line with the recommendations of the main international clinical guidelines and current scientific literature. The first reason not to prescribe lithium in our country is the perception of its adverse effects and not the aspects related to its practical use or its effectiveness. Considering that BD is a chronic disease with a typical onset in adolescence, the low rate of prescription of lithium salts in patients under 18 must be thoroughly studied.
Authors: C J Bachmann; L Aagaard; M Bernardo; L Brandt; M Cartabia; A Clavenna; A Coma Fusté; K Furu; K Garuoliené; F Hoffmann; S Hollingworth; K F Huybrechts; L J Kalverdijk; K Kawakami; H Kieler; T Kinoshita; S C López; J E Machado-Alba; M E Machado-Duque; M Mahesri; P S Nishtala; D Piovani; J Reutfors; L K Saastamoinen; I Sato; C C M Schuiling-Veninga; Y-C Shyu; D Siskind; S Skurtveit; H Verdoux; L-J Wang; C Zara Yahni; H Zoëga; D Taylor Journal: Acta Psychiatr Scand Date: 2017-05-14 Impact factor: 6.392
Authors: A Amerio; P Ossola; F Scagnelli; A Odone; M Allinovi; A Cavalli; J Iacopelli; M Tonna; C Marchesi; S N Ghaemi Journal: Eur Psychiatry Date: 2018-08-18 Impact factor: 5.361
Authors: Gerard Anmella; Isabella Pacchiarotti; Wiesław Jerzy Cubała; Dominika Dudek; Giuseppe Maina; Pierre Thomas; Eduard Vieta Journal: Eur Neuropsychopharmacol Date: 2019-10-04 Impact factor: 4.600
Authors: M Berk; O Dandash; R Daglas; S M Cotton; K Allott; A Fornito; C Suo; P Klauser; B Liberg; L Henry; C Macneil; M Hasty; P McGorry; C Pantelis; M Yücel Journal: Transl Psychiatry Date: 2017-01-24 Impact factor: 6.222